MUSCLE RELAXANT AND ANALGESIC CAPLETS TABLET

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

IBUPROFEN; METHOCARBAMOL

可用日期:

INTERNATIONAL PHARMACEUTICAL GENERICS LTD

ATC代码:

M03BA53

INN（国际名称）:

METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS

剂量:

200MG; 500MG

药物剂型:

TABLET

组成:

IBUPROFEN 200MG; METHOCARBAMOL 500MG

给药途径:

ORAL

每包单位数:

100

处方类型:

OTC

治疗领域:

CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS

產品總結:

Active ingredient group (AIG) number: 0248961001; AHFS:

授权状态:

CANCELLED PRE MARKET

授权日期:

2017-06-13

产品特点

1 | P a g e
PRODUCT MONOGRAPH
MUSCLE RELAXANT & ANALGESIC CAPLETS
500 MG METHOCARBAMOL AND 200 MG IBUPROFEN TABLETS
THERAPEUTIC CLASSIFICATION
MUSCLE RELAXANT / ANALGESIC
INTERNATIONAL PHARMACEUTICAL GENERICS LTD.,
Date of Preparation:
30 Malta Avenue, Suite 2408
February 01, 2010
Brampton, ON
L6Y 4S5
Control#: 135919
2 | P a g e
TABLE
OF CONTENTS
Clinical
Pharmacology..............................................................................................................................3
Indications:................................................................................................................................................7
Contraindications
......................................................................................................................................8
Warnings:..................................................................................................................................................8
Precautions..............................................................................................................................................12
Drug Interactions
....................................................................................................................................13
Adverse Reactions
..................................................................................................................................15
Symptoms and Treatment of
Overdose...................................................................................................17
Dosage and
Administration.....................................................................................................................18
Pharmaceutical
Information....................................................................................................................19
Composition:...........................................................................................................................................21
Availability of Dosage
Forms............